biostudies-literatureGoodman ALIntramural NIH HHSNIDDK NIH HHSMedical Research CouncilNational Institute for Health Research (NIHR)4601-12https://www.ebi.ac.uk/biostudies/studies/S-EPMC2976338biostudies-literatureUnknown78(11)Although merozoite surface protein 1 (MSP-1) is a leading candidate vaccine antigen for blood-stage malaria, its efficacy in clinical trials has been limited in part by antigenic polymorphism and potentially by the inability of protein-in-adjuvant vaccines to induce strong cellular immunity. Here we report the design of novel vectored Plasmodium falciparum vaccines capable of overcoming such limitations. We optimized an antigenic insert comprising the four conserved blocks of MSP-1 fused to tandemly arranged sequences that represent both allelic forms of the dimorphic 42-kDa C-terminal region. Inserts were expressed by adenoviral and poxviral vectors and employed in heterologous prime-boost regimens. Simian adenoviral vectors were used in an effort to circumvent preexisting immunity to humInfection and immunityNew candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.PMC2976338MC_U117532067NF-SI-0509-10233G0600424G1000527(95710)P30 DK047757P30 DK-47757G1000527G0700735Wilson JMLong CABiswas SGao GPHill AVRemarque EJGilbert SCEpp CGoodman ALSeibel Dvan Duivenvoorde LMMoss DAmmendola VColloca SDicks MDThomas AWHolder AADraper SJfalseNew candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.Although merozoite surface protein 1 (MSP-1) is a leading candidate vaccine antigen for blood-stage malaria, its efficacy in clinical trials has been limited in part by antigenic polymorphism and potentially by the inability of protein-in-adjuvant vaccines to induce strong cellular immunity. Here we report the design of novel vectored Plasmodium falciparum vaccines capable of overcoming such limitations. We optimized an antigenic insert comprising the four conserved blocks of MSP-1 fused to tandemly arranged sequences that represent both allelic forms of the dimorphic 42-kDa C-terminal region. Inserts were expressed by adenoviral and poxviral vectors and employed in heterologous prime-boost regimens. Simian adenoviral vectors were used in an effort to circumvent preexisting immunity to hum2010-01-01T00:00:00Z2010 Nov2025-04-05T14:45:31.424Z2019-03-27T00:36:28ZS-EPMC29763382071362310.1128/IAI.00315-1010.1128/iai.00315-10